AKT2 - AKT serine/threonine kinase 2 Gene

Also Known as PRKBB

Species: Sus scrofa

Gene Type: protein coding
Gene ID: 100127478

About AKT2

Primary_assembly 6: 48,555,795-48,587,919 reverse strand.Sscrofa11.1:CM000817.5

This gene has 4 transcripts (splice variants), 238 orthologues and 7 paralogues. Broad expression in subcutaneous adipose (RPKM 82.5), ovary (RPKM 16.6) and 8 other tissues.

AKT2 Products (1)

mRNA Protein Name
NM_001256779.1 NP_001243708.1 RAC-beta serine/threonine-protein kinase

AKT2 Protein Structure

PH_PKB

PH_PKB: cd01241 (3 - 112)

STKc_PKB_beta

STKc_PKB_beta: cd05595 (157 - 479)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 483 a.a.
Protein Preferred Names Protein Names

RAC-beta serine/threonine-protein kinase

  • protein kinase B beta

  • v-akt murine thymoma viral oncogene homolog 2

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-B0960 Sulfabenzamide 99.68% Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P99118 Serplulimab Inducer 99.30% Unkown

Clinical Phase

Bioactive Molecules (17)
Cat. No. Product Name Effect
Purity Phase
HY-15186 Ipatasertib Inhibitor 99.88% Phase 4
HY-N0004 Oridonin Inhibitor 99.89% Phase 4
HY-15431 Capivasertib Inhibitor 99.96% Phase 3
HY-15727 Afuresertib Inhibitor 99.53% Phase 3
HY-15186A Ipatasertib dihydrochloride Inhibitor 99.27% Phase 3
HY-19719 Miransertib Inhibitor 99.32% Phase 2
HY-15965 Uprosertib Inhibitor 99.93% Phase 2
HY-19934A Pifusertib hydrochloride Inhibitor 99.90% Phase 2
HY-15727A Afuresertib hydrochloride Inhibitor 99.95% Phase 2
HY-19719A Miransertib hydrochloride Inhibitor 99.74% Phase 2
HY-19934 Pifusertib Inhibitor 99.81% Phase 2
HY-15965A Uprosertib hydrochloride Inhibitor / Phase 2
HY-10358 MK-2206 dihydrochloride Inhibitor 99.99% Phase 1
HY-10249 GSK-690693 Inhibitor 99.03% Phase 1
HY-100018 BAY1125976 Inhibitor 99.52% Phase 1
HY-16071 AT13148 Inhibitor 99.20% Phase 1
HY-15186C Ipatasertib tosylate Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (26)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-10355 AKT inhibitor VIII Inhibitor 98.97% Unkown
HY-108232 MK-2206 Inhibitor 99.72% Unkown
HY-10425 Rizavasertib Inhibitor 99.04% Unkown
HY-133120 INY-03-041 Inhibitor 99.74% Unkown
HY-13260 CCT128930 Inhibitor 99.69% Unkown
HY-151504 Engasertib Inhibitor 99.65% Unkown
HY-12059 AT7867 Inhibitor 99.85% Unkown
HY-137458A Vevorisertib trihydrochloride Inhibitor 98.05% Unkown
HY-19982 AKT-IN-6 Inhibitor 99.08% Unkown
HY-50862 Akt1/Akt2-IN-1 Inhibitor 99.30% Unkown
HY-145282 MS170 Inhibitor 98.68% Unkown
HY-12059A AT7867 dihydrochloride Inhibitor 99.73% Unkown
HY-137458 Vevorisertib Inhibitor 98.03% Unkown
HY-133120A INY-03-041 trihydrochloride Inhibitor 99.78% Unkown
HY-132302 Hu7691 Inhibitor 99.91% Unkown
HY-13260A CCT128930 hydrochloride Inhibitor 98.97% Unkown
HY-16666 3CAI Inhibitor 98.32% Unkown
HY-129119 Akt1/Akt2-IN-2 Inhibitor 98.57% Unkown
HY-151613 MS15 Inhibitor / Unkown
HY-126257 AKT-IN-3 Inhibitor 98.12% Unkown
HY-145281 MS98 Inhibitor / Unkown
HY-132302A Hu7691 free base Inhibitor / Unkown
HY-10357 MK-2206 free base Inhibitor / Unkown
HY-138767 AKT-IN-5 Inhibitor / Unkown
HY-143611 AKT-IN-8 Inhibitor / Unkown
HY-16032 Akt1-IN-2 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens AKT2 NCBI NCBI:208